Ivabradin Pharmathen

Ivabradine, the active ingredient in Ivabradin Pharmathen, is an If channel inhibitor presented as an oral formulation for oral use. It is employed to lower heart rate in patients with chronic stable angina and in those with heart failure, improving symptom control.

GNH USA supplies Ivabradin Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Its global network ensures reliable delivery to diverse healthcare settings.

Ivabradine acts on the cardiac conduction system to reduce heart rate, benefiting conditions characterized by angina or heart failure. - Chronic stable angina: decreases frequency of angina episodes by lowering myocardial oxygen demand. - Heart failure: improves functional capacity and reduces hospitalisation risk by maintaining a lower heart rate.

Ivabradine may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: excessively low heart rate. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Atrial fibrillation: new onset irregular heart rhythm. - Severe hypotension: marked drop in blood pressure. - Vision loss: persistent visual impairment.

When prescribing Ivabradine, clinicians should observe specific precautions to ensure safe use. - Baseline heart rate: confirm resting rate ≥60 bpm before initiation. - Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses. - Severe hepatic impairment: use with caution or avoid. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Ivabradine interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels. - Other heart‑rate lowering agents (e.g., digoxin, beta‑blockers) combined without monitoring: risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive drugs: monitor blood pressure for additive effects.